GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

MedicalSystem Biotechnology Co 300439.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

9.52

-1.35%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About MedicalSystem Biotechnology Co

Its shares trade on Shenzhen under the ticker 300439.SZ. It has been listed since 22 April 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.54bn and net income of CN¥63.2m. At that date it held total assets of CN¥3.65bn and shareholders' equity of CN¥2.95bn.

MedicalSystem Biotechnology Co., Ltd. engages in the research, development and manufacturing of bio-tech pharmaceutical products. The company is headquartered in Ningbo, Zhejiang. The company went IPO on 2015-04-22. The Company’s in-vitro diagnostic products include in-vitro diagnostic reagent and in-vitro diagnostic instrument. In addition, the Company is also involved in the provision of third-party medical diagnosis services, as well as the production and distribution of reagent raw materials. The firm mainly operates businesses in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
22 Apr 2015
Employees
2,473
Website
nbmksw.com ↗

Leadership

Pay as last reported

  • Mr. Bingde ZouChairman of the Board, since 2011CN¥1.2m
  • Ms. Huiping XiongChief Financial Officer, Deputy General Manager, Secretary of the BoardCN¥500,000
  • Mr. Jihua ZouGeneral Manager, Director, since 2016CN¥874,200
  • Mr. Liang FangDeputy General ManagerCN¥554,000
  • Mr. Min ShenDeputy General ManagerCN¥596,300
  • Mr. Gaipeng HuangDirectorCN¥582,800
  • Mr. Yunpeng TianIndependent DirectorCN¥100,000
  • Ms. Ling XuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Ningbo, Zhejiang with 2,473 employees
  • Engages in research, development, and manufacturing of bio-tech pharmaceutical products
  • Offers in-vitro diagnostic reagents and instruments as part of its product portfolio

Weaknesses

  • Relies solely on the domestic market for operations
  • No mention of international presence or global market expansion
  • Limited information on product diversification beyond diagnostic products

Opportunities

  • Potential growth in domestic health care sector
  • Expansion into international markets for diagnostic products
  • Opportunities to diversify into additional biotechnology product lines

Threats

  • Dependence on domestic market may limit growth potential
  • Competition from other domestic biotechnology firms
  • Lack of information on regulatory challenges in the industry

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.